Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast Cancer
Status:
Terminated
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide,
paclitaxel, and gemcitabine hydrochloride, work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies,
such as bevacizumab, can block tumor growth in different ways. Some block the ability of
tumor cells to grow and spread. Others find tumor cells and help kill them or carry
tumor-killing substances to them. Bevacizumab may also stop the growth of breast cancer by
blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab
after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This phase II trial is studying the side effects and how well giving combination
chemotherapy together with bevacizumab works in treating women with HER2/neu-negative stage
II or stage III breast cancer